|
|
|
| home > ebr > Spring 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
A Watchful Eye
Michael Rosenberg of Health Decisions Inc explains why monitoring is the single most important safeguard for clinical studies and considers the methods available for accurately gauging the trajectory of a trial.
|
|
|
Digital Directions
As the regulatory pressure on small and medium-sized companies increases, electronic document management system software is being tailored to maintain efficiency standards. Keith Williams of GxPi looks at how to implement these hosted systems to enhance functionality.
|
|
|
Blockbuster Takeover
The acquisition of Genzyme grabbed headlines as the largest pharmaceutical company takeover in the industry for years. Daniel Bastide from Thomas Eggar LLP reports on the negotiations that made the purchase possible.
|
|
|
Perfect Partnering
Ross McLennan of TMRI Ltd shows how a multitude of collaborations between industries can allow for stronger adaptive clinical designs, and details some of the initiates already in place that prove what they can offer.
|
|
|
Software Solutions
The burden of the industry’s livelihood is dependent on the success of partnerships. Alison Shurell at IntraLinks explains how embracing new technology can effectively speed up the communication chain.
|
|
|
|
Standing at the Threshold
Contemplating revisions to the blockbuster ‘one-size-fits-all’ business model, Private Consultant Emile Bellott highlights the reasons why applying genetic-aware therapeutic strategies presents a compelling opportunity for the major industry players.
|
|
|
Accelerating Innovative Vaccines
Scott Preiss, Alberta Di Pasquale, Marleen Mergaerts and Nathalie Garçon at GlaxoSmithKline Biologics discuss vaccines in common use and the factors that go into narrowing down their design goals.
|
|
|
Learning from Experience
Using examples of exogenous virus contamination, Andy Bailey of ViruSure GmbH reviews the vulnerability of the biotech manufacturing process from sources yet to be identified.
|
|
|
Mind the Messenger
Raymond Verhaert and Victor Schut of ProteoNic review the technology affecting translational activity, with specific focus on their application to the study of mammalian and yeast cell culture.
|
|
|
|
|
Stem Cell Innovation
Vanessa Ott and Blake Anson of Cellular Dynamics International look at how the world of induced pluripotent stem cells has changed since it was discovered that they could be extended to human cells.
|
|
|
Big Ideas on a Small Scale
The successful development of miniaturised, automated, speedy and reliable assays in the future will be heavily dependent on nanotechnology, suggests Mike Fisher at NanoKTN in this portrait of what is available currently.
|
|
|
|
Best Practices
Nathalie A Compagnone of Innovative Concepts in Drug Development examines the role of regulatory agencies in diagnostic testing and biomarker development.
|
|
|
New Horizons
Focusing on the rise of the ‘omics’ field, Gustavo Salem of Agilent Technologies, Inc considers the future of integrated biology and explains how a deeper understanding of cellular processes is set to alter the way we view therapeutics.
|
|
|
|
From Lab to Clinic
When streamlining a business, often one of the strongest ways to ensure you have all the necessary expertise is to outsource. Angela Scott and Susan McKee of Angel Biotechnology evaluate the risks and benefits of biomanufacturing using external contractors.
|
|
|
The Perfect Host
John Liddell and Ian Hodgson of MSD BioManufacturing Network demonstrate that if molecule expression can be achieved in E Coli, then lower costs and a faster speed to market will usually follow.
|
|
|
Sustainable Standards
Yaniv Vardi at Sparta Systems Europe Ltd assesses how crucial the enterprise-wide quality management system is in the pharmaceutical and biotechnology industries.
|
|
|
|
Dragon’s Den
In a comparison of the biotech industry’s US and Chinese workforces, Erik Lundh of J. Robert Scott draws on recent survey findings to report on top hiring issues and the international effect of the ‘brain drain’.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Dempsey Demystifies Regulatory Cycle at DIA Europe
March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director,
Sheena Dempsey, will present “Demystifying the Multilingual Complexities
in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM
(CET), in Basel, Switzerland.
More info >> |
|
 |
White Papers |
 |
|
Crossing the Blood Brain Barrier (BBB): Which Route to Take?
Aptar Pharma
Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >> |
|
 |
Industry Events |
 |
PPMA SHOW 2018
25-27 September 2018, NEC, Birmingham, UK
The UK’s leading production line event is celebrating
its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27
September 2018, the exhibition showcases the latest processing and packaging
machinery. Attended by thousands of manufacturers of food, pharmaceuticals and
FMCG as well as contract packers and more.
More info >> |
|
|
